Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
What the clinical data has reported: Phase 2 trials of Retatrutide (Jastreboff et al., NEJM 2023, and follow-ups) reported: - Dose-dependent body weight reduction across 24- and 48-week dosing intervals - Reductions in liver fat content measured by MRI-proton density fat fraction (MRI-PDFF) in populations with metabolic dysfunction-associated steatotic liver disease (MASLD) - Glycaemic marker improvement (HbA1c, fasting glucose) in type 2 diabetes cohorts - Dose-related gastrointestinal adverse effects consistent with the GLP-1/GIP class nausea, vomiting, diarrhoea Important: these are clinical trial findings in regulated patient populations
VLP, Virus-like peptide
About Safety: What are the documented side effects
Medications like Semaglutide GLP-1, which mimic the natural GLP-1 hormone , are used as effective treatments for weight loss when combined with healthy lifestyle changes, nutrition, and exercise
US$ 23.87
US$ 29.80
US$ 27.48
US$ 25.76
US$ 29.14
US$ 20.36
US$ 27.19
